Repligen (RGEN) has been under pressure after a weaker February jobs report hit healthcare stocks, even as the company recently reported quarterly and full year 2025 results that showed positive revenue and net income figures.
See our latest analysis for Repligen.
At a share price of US$119.99, Repligen has seen a 1 day share price return of 4.03% decline, a 30 day share price return of 15.61% decline, and a 1 year total shareholder return of 22.94% decline. This suggests momentum has been fading as investors weigh improving earnings against concerns over margins, scale and the broader pullback in healthcare stocks after the weaker jobs report and recent critical research.
If Repligen’s recent swings have you reassessing the sector, it could be a good moment to widen your watchlist with our screener of 32 healthcare AI stocks as potential new ideas.
With earnings now back in positive territory and the share price still under pressure, the key question is whether Repligen’s recent weakness has gone too far, creating an opportunity, or whether the market is already correctly pricing in its future growth.
Most Popular Narrative: 37.1% Undervalued
Repligen’s most followed valuation story pegs fair value at $190.89, well above the recent US$119.99 close. This sets up a clear gap for investors to assess.
Strong and sustained order growth across biopharma, CDMO, and capital equipment segments supported by record multi quarter book to bill ratios and a robust funnel positions the company for above market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises.
Read the complete narrative. Read the complete narrative.
Want to see what is driving that higher fair value? The narrative focuses on compounding revenue, rising profitability, and a rich earnings multiple. Curious how those pieces fit together to reach US$190.89?
Result: Fair Value of $190.89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story still hinges on biotech funding stabilising and gene therapy demand improving. Both areas have seen recent softness that could undermine those optimistic assumptions.
Find out about the key risks to this Repligen narrative.
Another Angle: Rich Multiple Tells A Different Story
On earnings, Repligen looks expensive. The shares trade on a P/E of about 138x, compared with roughly 34x for the US Life Sciences industry and 37x for peers. Our fair ratio sits nearer 26x, and that gap suggests plenty of valuation risk if expectations cool.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of caution and optimism feels familiar, it may be a good time to look at the numbers yourself and act while sentiment remains mixed. To see exactly what the market seems most hopeful about, take a closer look at the 4 key rewards.
Looking for more investment ideas?
If you want to keep building your edge, use the Simply Wall St Screener to spot other opportunities before they sit on the front page.
- Target quality at a discount by scanning our 49 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their potential.
- Prioritise staying power by checking companies in the solid balance sheet and fundamentals stocks screener (41 results) that focus on resilience through stronger financial footing.
- Balance income and caution by reviewing the 63 resilient stocks with low risk scores that may suit investors who prefer steadier profiles over sharp swings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com